Drug Trial Radar · NCT00975897
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,240
Planned (sponsor's estimate)
Start
Jul 2009
Primary completion
Aug 2010
Study completion Dec 2012
Sponsor
- Lead sponsor
- Medical Research CouncilGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Sep 14, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors select the best treatment for patients and predict their response to treatment. PURPOSE: This randomized phase II/III trial is studying how well tumor tissue testing works in selecting treatment for patients with metastatic or locally advanced colorectal cancer.
Conditions
- Colorectal Cancer
Interventions
bevacizumabBiological
cetuximabBiological
fluorouracilDrug
irinotecan hydrochlorideDrug
leucovorin calciumDrug
oxaliplatinDrug
RNA analysisGenetic
cytogenetic analysisGenetic
fluorescence in situ hybridizationGenetic
gene expression analysisGenetic
mutation analysisGenetic
protein expression analysisGenetic
diagnostic laboratory biomarker analysisOther
immunohistochemistry staining methodOther
questionnaire administrationOther
cognitive assessmentProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Topoisomerase-1 (topo-1) and K-ras, BRAF results obtained within 10 working days after registration
- Number of patients in which the interval between registration and randomization (RZ) is ≤ 10 days
- Efficacy of fluorouracil with vs without irinotecan hydrochloride, fluorouracil, and leucovorin calcium (IrMdG) in low topo-1 tumors
- Progression-free survival of patients with high topo-1 tumors treated with IrMdG with or without oxaliplatin
- Efficacy of IrMdG with vs without cetuximab in K-ras wildtype tumors
- Efficacy of IrMdG with vs without bevacizumab in K-ras mutant tumors
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom
Belfast City Hospital Trust Incorporating Belvoir Park Hospital
Belfast, Northern Ireland, United Kingdom
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.